Ordered mesoporous silica material SBA-15: A broad-spectrum formulation platform for poorly soluble drugs

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2648-2658

  Van Speybroeck, Michiel ^a   Barillaro, Valéry ^a   Thi, Thao Do ^a   Mellaerts, Randy ^b   Martens, Johan ^b   Van Humbeeck, Jan ^b   Vermant, Jan ^b   Annaert, Pieter ^a   Van Den Mooter, Guy ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adsorption; Dissolution; Mesoporous silica SBA 15; Physical characterization; Physical stability; Poor solubility

Indexed keywords

CARBAMAZEPINE; CINNARIZINE; DANAZOL; DIAZEPAM; EXCIPIENT; FENOFIBRATE; GRISEOFULVIN; INDOMETACIN; KETOCONAZOLE; NIFEDIPINE; PHENYLBUTAZONE; SBA 15; SILICATE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STORAGE; IN VITRO STUDY; PHYSICAL CHEMISTRY;

EID: 68249102027     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21638     Document Type: Article

References (49)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26. (Pubitemid 33653411)
3. Alsenz J, Kansy M. 2007. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev 59:546-567. (Pubitemid 47285404)
4. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31:249-261. (Pubitemid 47079001)
5. Monkhouse DC, Lach JL. 1972. Use of adsorbents in enhancement of drug dissolution. II. J Pharm Sci 61:1435-1441.
6. Monkhouse DC, Lach JL. 1972. Use of adsorbents in enhancement of drug dissolution. I. J Pharm Sci 61:1430-1435.
7. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson G, Chmelka B, Stucky G. 1998. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science 279:548-552. (Pubitemid 28067280)
8. IUPAC Manual of Symbols and Terminology, Appendix 2, Pt. 1, Colloid and Surface Chemistry. 1972.
9. Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. 1992. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359:710-712.
10. Vallet-Regi M, Ramilla A, del Real RP, Perez-Pariente J. 2001. A new property of MCM-41: Drug delivery system. Chem Mater 13:308-311. (Pubitemid 32199334)
11. Heikkilä T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, Hirvonen J, Lehto V. 2007. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 14:337-347. (Pubitemid 47265819)
12. Mellaerts R, Aerts CA, Van Humbeeck J, Augustijns P, Van den Mooter G, Martens JA. 2007. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem Commun 1375-1377. (Pubitemid 46465984)
13. Tozuka Y, Wongmekiat A, Kimura K, Moribe K, Yamamura S, Yamamoto K. 2005. Effect of pore size of FSM-16 on the entrapment of flurbiprofen in mesoporous structures. Chem Pharm Bull (Tokyo) 53:974-977. (Pubitemid 41327690)
14. Andersson J, Rosenholm J, Areva S, Lindén M. 2004. Influences of material characterisitics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices. Chem Mater 16:4160-4167.
15. Azaïs T, Tourné-Péteilh C, Aussenac F, Baccile N, Coelho C, Devoiselle J, Babonneau F. 2006. Solid-state NMR study of ibuprofen confined in MCM-41 material. Chem Mater 18:6382-6390. (Pubitemid 46132802)
16. Babonneau F, Yeung L, Steunou N, Gervais C, Ramila A, Vallet-Regi M. 2004. Solid state NMR characterisation of encapsulated molecules in mesoporous silica. J Sol-Gel Sci Technol 31:223.
17. Cavallaro G, Pierro P, Palumbo F, Testa F, Pasqua L, Aiello R. 2004. Drug delivery devices based on mesoporous silicate. Drug Deliv 11:46. (Pubitemid 38292726)
18. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. 2004. Inclusion of ibuprofen in mesoporous templated silica: Drug loading and release property. Eur J Pharm Biopharm 57:533-540. (Pubitemid 38490572)
19. Heikkilä T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar N, Salmi T, Murzin DY, Laitinen L, Kaukonen AM, Hirvonen J, Lehto V. 2007. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm 331:133-138. (Pubitemid 46176505)
20. Horcajada P, Ramila A, Perez-Pariente J, Vallet-Regi M. 2004. Influence of pore size of MCM-41 matrices on drug delivery rate. Micropor Mesopor Mater 68:109. (Pubitemid 38265756)
21. Izquierdo-Barba I, Martinez A, Doadrio AL, Pérez-Pariente J, Vallet-Regí M. 2005. Release evaluation of drugs from ordered three-dimensional silica structures. Eur J Pharm Sci 26:365-373. (Pubitemid 41551570)
22. Qu F, Zhu G, Huang S, Li S, Sun J, Zhang D, Qiu S. 2006. Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica. Micropor Mesopor Mater 92:1-9. (Pubitemid 43782508)
23. Ramila A, Munoz B, Perez-Pariente J, Vallet-Regi M. 2003. Mesoporous MCM-41 as drug host system. J Sol-Gel Sci Technol 26:1202.
24. Song S, Hidajat K, Kawi S. 2005. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions. Langmuir 21:9568-9575. (Pubitemid 41507008)
25. Tourne-Peteilh C, Brunel D, Begu S, Chiche B, Fajula F, Lerner D, Devoisselle J. 2003. Synthesis and characterisation of ibuprofen-anchored MCM-41 silica and silica gel. New J Chem 27:1418. (Pubitemid 37289995)
26. Mellaerts R, Mols R, Jammaer JAG, Aerts CA, Annaert P, Van Humbeeck J, Van den Mooter G, Augustijns P, Martens JA. 2008. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm 69:223-2230.
27. Ambrogi V, Perioli L, Marmottini F, Giovagnoli S, Esposito M, Rossi C. 2007. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur J Pharm Sci 32:216-222. (Pubitemid 47532714)
28. Kruk M, Jaroniec M, Ko C, Ryoo R. 2000. Characterization of the porous structure of SBA-15. Chem Mater 12:1968.
29. Galarneau A, Nader M, Guenneau F, DiRenzo F, Gedeon A. 2007. Understanding the stability in water of mesoporous SBA-15 and MCM-41. J Phys Chem 111:8268-8277. (Pubitemid 47012680)
30. Kosuge K, Sato T, Kikukawa N, Takemori M. 2004. Morphological control of rod- and fiberlike SBA-15 type mesoporous silica using water-soluble sodium silicate. Chem Mater 16:899-905.
31. Brunauer S, Emmett PH, Teller E. 1938. Adsorption of gases in multimolecular layers. J Am Chem Soc 60:309-319.
32. Lippens BC, De Boer JH. 1965. Studies on pore systems in catalysts. V. The t-method. J Catal 4: 319-323.
33. Barrett EP, Joyner LG, Halenda PP. 1951. The determination of pore volume and area distribution in porous substances. J Am Chem Soc 73:373-380.
34. Sethia S, Squillante E. 2004. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 272:1-10. (Pubitemid 38293005)
35. Verheyen S, Blaton N, Kinget R, Van den Mooter G. 2002. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm 249:45-58. (Pubitemid 35333431)
36. Dosseh G, Xia Y, Alba-Simionesco C. 2003. Cyclohexane and benzene confined in MCM-41 and SBA-15: Confinement effects on freezing and melting. J Phys Chem 107:6445-6453.
37. Morishige K, Kawano K. 2000. Freezing and melting of methanol in a single cylindrical pore: Dynamical supercooling and vitrification of methanol. J Chem Phys 112:11023-11029. (Pubitemid 30876050)
38. Radhakrishnan R, Gubbins KE, Sliwinska-Bartkowiak M. 2000. Effect of the fluid-wall interaction on freezing of confined fluids: Toward the development of a global phase diagram. J Chem Phys 112:11048-11057. (Pubitemid 30876047)
39. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12. (Pubitemid 127489650)
40. Aerts C, Verraedt E, Mellaerts R, Depla A, Augustijns P, VanHumbeeck J, VandenMooter G, Martens J. 2007. Tunability of pore diameter and particle size of amorphous microporous silica for diffusive controlled release of drug compounds. J Phys Chem C 111:13404-13409. (Pubitemid 47481931)
41. Icenhower J, Dove P. 2000. Water behavior at silica surfaces. In: Papirer E, editor. Adsorption on silica surfaces. New York: Marcel Dekker, Inc.
42. Tozuka Y, Oguchi T, Yamamoto K. 2003. Adsorption and entrapment of salicylamide molecules into the mesoporous structure of folded sheets mesoporous material (FSM-16). Pharm Res 20: 926-930. (Pubitemid 36628441)
43. Ambrogi V, Perioli L, Marmottini F, Accorsi O, Pagano C, Ricci M, Rossi C. 2008. Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Micropor Mesopor Mater 113:445-452.
44. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. 2001. Stability of amorphous indomethacin compounded with silica. Int J Pharm 226:81-91. (Pubitemid 32800785)
45. Friedrich H, Fussnegger B, Kolter K, Bodmeier R. 2006. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm 62:171-177. (Pubitemid 43143269)
46. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60. (Pubitemid 30326688)
47. Serajuddin AT. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
48. Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
49. Davis ME, Brewster ME. 2004. Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov 3:1023-1035. (Pubitemid 39642365)